loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Shalby Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Shalby Ltd. 04 Feb 2025 11:34 AM
Result PDF

Q3FY25 Quarterly Result Announced for Shalby Ltd.

Healthcare Facilities company Shalby announced Q3FY25 results

  • Consolidated Revenue at Rs 2,811 million in Q3FY25.
  • Consolidated EBITDA at Rs 393 million in Q3FY25.
  • Consolidated PBT at Rs 124 million in Q3FY25.
  • Occupied Bed during the quarter were 646.
  • In patient count (incl. Day Care) of 22,369 growth of 7.9% YoY.
  • ARPOB during the quarter was 42,704, growth of 14.4% YoY.

Shanay Shah, President, Shalby, said: The company has shown a decent consolidated performance in Q3FY25 with a revenue of 281 crore with growth of 27.4% on YoY basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year.

I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 7.9% rise in In-patient count (including day care) year-on-year in Q3FY25. Notably, ARPOB and ALOS stood at Rs 42,704 and 3.62 respectively in Q3FY25, compared to Rs 37,342 and 3.79 in the corresponding quarter of the previous year improved by 14.4% and 4.5% respectively. Our core specialties, including Arthroplasty, Onco-Science, Cardiac Science, Orthopaedic, Critical Care & General Medicine, and Neurology, collectively contributed 80% to the revenues in Q3FY25.

On a standalone performance, our revenue has grown by 13.3% to Rs 227 crore and EBITDA has grown marginally by 0.8% to Rs 48.8 crore with the EBITDA margin of 21.5% on YoY basis.

Our Homecare business contributed Rs 3.6 crore in Q3FY25 compared to Rs 3.4 crore in Q3FY24. Additionally, our Shalby Academy vertical witnessed an encouraging response, with over 1000 students enrolled in various healthcare programs during Q3FY25.

Furthermore, our Realized Return on Capital Employed from the hospital business stood at 15% in Q3’FY25 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 2,667 million, with a net cash balance of Rs 660 million at the standalone level, reinforcing our ability to support strategic growth initiatives.

In January’25 Shalby Bone and Tissue Bank has been successfully inaugurated by our Hon’ble Union Home Minister of India, Shri Amit Shah at our Krishna Shalby Hospital in Ahmedabad. Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people'slives.

Deepak Anand, Global Chief Business Officer, said: During the third quarter of this financial year, our implant business made significant progress, generating revenues of Rs 269 million up by 25% YOY, with contributions from the USA and OUS at 33% and 67% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the South Asian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries.

With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth with sustainable profitability, while also expanding and deepening our presence by opening up new geographies. These efforts will ultimately drive the creation of sustainable value for allstakeholders at Shalby.

Result PDF

Result PDF

Healthcare Facilities company Shalby announced Q2FY25 results

  • Consolidated Revenue at Rs 2,747 million in Q2FY25.
  • Consolidated EBITDA at Rs 398 million in Q2FY25.
  • Consolidated PBT at Rs 137 million in Q2FY25.
  • Occupied Bed during the quarter were 690.
  • In patient count (incl. Day Care) of 23,907, growth of 5.5% YoY.
  • ARPOB during the quarter was 38,779, growth of 7.3% YoY.

Shanay Shah, President, Shalby, said: The company has shown a decent consolidated performance in Q2FY25 with a revenue of 275 crore with growth of 12.7% on YoY basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year.

I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 5.5% rise in In-patient count (including day care) year-on-year in Q2FY25. Notably, ARPOB and ALOS stood at Rs 38,779 and 3.6 respectively in Q2FY25, compared to Rs 36,136 and 3.92 in the corresponding quarter of the previous year improved by 7.3% and 8.2% respectively. Our core specialties, including Arthroplasty, Onco-Science, Cardiac Science, Orthopaedic, Critical Care & General Medicine, and Neurology, collectively contributed 80% to the revenues in Q2FY25.

On a standalone performance, our revenue has de-grown by 2.4% due to reduction in Surgeries by 7% on YoY basis. Rajasthan and Gujarat had witnessed a major rain fall in Q2FY25, where most districts in Gujarat and Rajasthan experienced heavy flooding which resulted in patients postponing elective surgeries. This resulted the major dip in surgeries in the Arthroplasty business as well as other specialities. Our EBIDTA on stand-alone performance has de-grown due to the above reason which has resulted in higher expenses in proportion to revenue.

Our Homecare business contributed Rs 3.88 crore in Q2FY25 compared to Rs 3.64 crore in Q1FY24. Additionally, our Shalby Academy vertical witnessed an encouraging response, with over 1135 students enrolled in various healthcare programs during Q2FY25.

Furthermore, our Realized Return on Capital Employed from the hospital business stood at 15% in Q2FY25 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 2,047 million, with a net cash balance of Rs 742 million at the standalone level, reinforcing our ability to support strategic growth initiatives.

Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people's lives.

Deepak Anand, Global Chief Business Officer, Shalby, said: During the second quarter of this financial year, our implant business made significant progress, generating revenues of Rs 278 million up by 90% YOY, with contributionsfrom the USA and OUS at 30% and 70% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the Indonesian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries.

With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth with sustainable profitability, while also expanding and deepening our presence by opening up new geographies. These efforts will ultimately drive the creation of sustainable value for allstakeholders at Shalby.

Result PDF

Healthcare Facilities company Shalby announced Q1FY25 results:

Consolidated:

  • Revenue at Rs 2,886 million in Q1FY25 vs Rs 2,400 million in Q1FY24 grew by 20.2% YoY
  • EBITDA at Rs 549 million in Q1FY25 vs Rs 477 million in Q1FY24 grew by 15.1% YoY
  • PBT at Rs 304 million in Q1FY25 vs Rs 330 million in Q1FY24
  • PAT at Rs 147 million in Q1FY25 vs Rs 208 million in Q1FY24
  • Net debt stood at Rs 1,680 million as on June’24
  • Annualized ROCE for Q1FY25 stood at 13.6%

Standalone:

  • Revenue at Rs 2,402 million in Q1FY25 vs Rs 2,163 million in Q1FY24 grew by 11.06% YoY
  • EBITDA at Rs 581 million in Q1FY25 vs Rs 497 million in Q1FY24 grew by 16.6% YoY
  • PBT at Rs 458 million in Q1FY25 vs Rs 400 million in Q1FY24
  • PAT at Rs 305 million in Q1FY25 vs Rs 262 million in Q1FY24
  • Net cash stood at Rs 627 million as on June’24
  • Annualized ROCE for Q1FY25 stood at 16%

 

Result PDF

 

Healthcare Facilities company Shalby announced Q4FY24 results:

  • Consolidated Revenue at Rs 2,492 million in Q4 FY24 grew by 19.7% YoY
  • Consolidated EBITDA at Rs 439 million in Q4 FY24 grew by 26.1% YoY
  • Consolidated PAT at Rs 168 million in Q4 FY24 grew by 42% YoY
  • Basic EPS of Rs 1.49 during the quarter, growth of 15.5% YoY
  • Occupied Bed during the quarter were 637, growth of 10.0% YoY
  • In patient count (incl. Day Care) of 21,313, growth of 14.9% YoY
  • ARPOB during the quarter was 39,101, growth of 12.1% YoY

Shanay Shah, President said: It has been a landmark here for the company, we have completed 30 years of operations in this year. The company continued to show a steady performance in FY 24 with a revenue of 953 crores and an EBITDA of 197 crores which is a growth of 15% and 23% respectively from the last financial year.

I'm pleased to announce that our hospital business has maintained consistent performance across key operational and financial metrics, witnessing a 10.0% increase in occupancy and a 14.9% rise in in-patient count (including day care) year-on-year in Q4 FY24. Additionally, hospital revenue and EBITDA grew by 14.8% and 16.8% respectively, with a robust EBITDA margin of 20.2% in the same period. Notably, ARPOB and ALOS stood at Rs.39,101 and 3.75 respectively in Q4 FY24, compared to Rs 34,867 and 4.01 in the corresponding quarter of the previous year. Our core specialties, including Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical Care & General Medicine, and Neurology, collectively contributed 82% to the revenues in Q4 FY24.

We are pleased to announce our strategic foray into northern India through the acquisition of 100% stake in Healers Hospital Pvt. Ltd. (Land & Building of Sanar). Sanar International hospital, with an operational capacity of 130 Beds, offers advanced surgical care across specialties such as Oncology, Cardiology, Bone Marrow Transplant, Kidney & Liver Transplant, Bone & Joint, and Neurosciences, with 70% business from international markets serving over 60 countries.

Our Homecare business exhibited robust growth, increasing by 36% year-on-year in Q4 FY24 compared to Q4 FY23. Additionally, our Shalby Academy vertical witnessed an encouraging response, with over 395 students enrolled in various healthcare programs during Q4 FY24.

Furthermore, our Realized Return on Capital Employed from the hospital business stood at 18% in FY24 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 1,557 million, with a net cash balance of Rs 220 million at the standalone level, reinforcing our ability to support strategic growth initiatives.

Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people's lives.

Deepak Ananthakrishnan, Global Chief Business Officer said: During the fourth quarter of this financial year, our implant business made significant progress, generating revenues of Rs 258 million, with contributions from the USA and India at 41% and 59% respectively. In Q4 FY24, our US customer sales mix from retail and wholesale remained at 55% and 45% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby-Consensus implants in our hospitals has been highly positive, and we have received additional orders from the Indonesian market.

With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth in the hospital business with sustainable profitability, while also expanding and deepening our presence by adding Orthopedic units under SOCE. These efforts will ultimately drive the creation of sustainable value for all stakeholders at Shalby.

Result PDF

Healthcare Facilities company Shalby announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Revenues of Rs 2,400 million, growth of 15% QoQ and 17% YoY
    • EBITDA of Rs 477 million, growth of 37% QoQ and 8% YoY
    • PBT of Rs 330 million, growth of 72% QoQ and 8% YoY
    • Basic EPS of Rs 1.94 during the quarter, growth of 50% QoQ
  • Standalone Q1FY24:
    • Revenues of Rs 2,164 million, growth of 18% QoQ and 20% YoY
    • EBITDA of Rs 497 million, growth of 36% QoQ and 16% YoY
    • PBT of Rs 400 million, growth of 51% QoQ and 22% YoY
    • EBITDA margin of 23% in Q1FY24 v/s 20% in Q4FY23 and 23.6% in Q1FY23
    • In-patient count (incl. Day Care) of 20,661, growth of 11% QoQ and 24% YoY
    • Total Surgery count of 8,183, growth of 25% QoQ and 14% YoY
    • Occupancy rate at 50% in Q1FY24 v/s 46% in Q4FY23 and 45% in Q1FY23
    • ARPOB during the quarter was 38,000, a growth of 9% QoQ and 8% YoY

Shanay Shah, President, Shalby, said: “I am very happy to report that this quarter reflected our best hospital business performance so far, across most financial and operating parameters, recording significant growth year-on-year and quarter-on-quarter. I am also proud to say that Shalby has achieved a landmark of 150,000 joint replacement surgeries (since inception) in Q1FY24 and with this we continue to maintain the leadership position in global volumes in the Orthopedics segment.

Our hospital business continued to grow high double-digit in the key metrics of In-Patient counts and surgery counts, growing by 24% and 14% respectively YoY in Q1FY24. Our hospital occupancy levels improved by 12% YoY and 8% QoQ and recorded a 50% occupancy rate in Q1FY24. ARPOB and ALOS were recorded at Rs 38,000 and 3.97 respectively in Q1FY24 vis-à-vis Rs 35,304 and 4.08 in the same quarter of the previous year.

Hospital revenue and EBITDA also grew by 18% and 36% QoQ respectively and 20% and 16% YoY respectively with a robust EBITDA margin of 23% in Q1FY24 v/s 20% in Q4 FY23. Our core specialties like Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 85% to the revenues in Q1FY24.

Our Homecare business demonstrated a strong performance in Q1FY24, growing by 70% YoY and 30% QoQ. International revenue continued to grow in Q1FY24 from Q1FY23 whereby the majority of the patients came from East African countries. Shalby also takes pride in nurturing young talent through our Shalby Academy vertical with 290 students registered in the various healthcare programs during Q1FY24.

Realized Return on Capital Employed from hospital business recorded at 20% in Q1FY24 on an annualized basis. We have closed the quarter with a net cash balance of Rs 806 million at the group level and are well-positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient care. We remain committed to making a positive difference in people's lives."

 

Result PDF

Healthcare Facilities company Shalby announced Q4FY23 & FY23 results:

Consolidated Q4FY23:

  • Revenues of Rs 2,082 million, growth of 25% YoY
  • EBITDA of Rs 348 million, growth of 23% YoY
  • Profit After Tax was Rs 139 million, growth of 37% YoY
  • Occupied Bed during the quarter were 579, growth of 16% YoY
  • In patient count (incl. Day Care) of 18,551, growth of 24% YoY
  • Total Surgery count of 6,553, growth of 18% YoY

Consolidated FY23:

  • Consolidated Revenues of Rs 8,274 million, growth of 16% YoY
  • Consolidated EBITDA of Rs 1,593 million, growth of 20% YoY
  • Consolidated Profit After Tax was Rs 677 million, growth of 25% YoY
  • In patient count (incl. Day Care) of 71,893, growth of 18% YoY
  • Total Surgery count of 27,352, growth of 35% YoY
  • ARPOB for full year was 34,842, growth of 11% YoY
  • Net cash (after deducting debt) at group level stood at Rs 712 million in FY23 v/s Rs 475 mn in FY22
  • Board has declared dividend of Rs 1.20 per share (12% of face value)

Mr. Shanay Shah, President said: “I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with surgery count and In-patient count (Incl day care) grew by 35% and 18% YoY respectively in full year FY23. Hospital revenue (Rs.7,274 mn) and EBITDA (Rs.1615 mn) grew by 11% and 13% YoY with robust EBITDA margin of 22% in full year FY23.

ARPOB and ALOS were recorded at Rs.34,842 and 3.92 respectively in FY23 vis-à-vis Rs 31,347 and 4.55 in the previous year. Our core specialties such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, Neurology and Nephrology contributed 88% to the revenues respectively in FY23.

International revenue of Rs. 104 million in FY23 grew by 144% YoY from FY22 whereby majority of the patients came from East African countries. Our homecare business also showed a strong performance with revenue grew by 38% YoY in FY23 at Rs.9.8 million, from FY22. The Shalby Academy vertical also showed an encouraging response with 2000 students enrolled for various healthcare programs during FY23.

Our Realized Return on Capital Employed from hospital business recorded at 16% in FY23 on an annualized basis v/s 14% in FY22. We have closed the quarter with a net cash balance of Rs. 712 million at the group level and are well positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient satisfaction and we feel proud to make a positive difference in people’s lives."

Result PDF

Healthcare facilities company Shalby announced Q3FY23 results:

  • Consolidated Q3FY23:
    • Consolidated Revenues of Rs 2,067 million, growth of 25.1% YoY
    • Consolidated EBITDA of Rs 380 million, growth of 22.5% YoY
    • Consolidated Profit After Tax was Rs 153 million, growth of 18% YoY
    • Basic EPS of Rs 1.42 during the quarter, growth of 19% YoY
    • Occupied Bed during the quarter were 544, growth of 6% YoY
    • In patient count (incl. Day Care) of 18,000, growth of 15% YoY
    • Total Surgery count of 6,782, growth of 19.4% YoY
    • ARPOB during the quarter was 36,291, growth of 13% YoY

Mr. Shanay Shah, President said: “I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with surgery count and In-patient count (Incl day care) grew by 19% and 15% Y-o-Y respectively in Q3 FY23. Hospital revenue and EBITDA also grew by 17.4% and 23.5% Yo-Y with robust EBITDA margin of 21.5% in Q3 FY23.

ARPOB and ALOS were recorded at Rs 36,291 and 3.74 respectively in Q3 FY23 vis-à-vis Rs 32,049 and 4.02 in the same quarter of the previous year. Our core specialties such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 85% to the revenues respectively in Q3 FY23.

International revenue continued to grow by 58% y-o-y in Q3 FY23 from Q3 FY22 whereby majority of the patients came from East African countries. Homecare business showed a strong performance grew by 42% y-o-y in Q3 FY23, from Q3 FY22. The Shalby Academy vertical also showed an encouraging response with 300 students enrolled for various healthcare programs during Q3 FY23.

Our Realized Return on Capital Employed from hospital business recorded at 16.3% in 9M FY23 on annualized basis. We have closed the quarter with a net cash balance of Rs. 376 million at group level and are well positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient satisfaction. We are proud to make a positive difference in people lives.

Mr. Sushobhan Dasgupta, Vice Chairman and Global President said: Other than Hospital business, our growth platforms like SOCE Franchise business and Implant business have also delivered healthy performance in Q3 FY23. I am happy to inform that our Lucknow SOCE unit has been fully operationalized from November 2022 and Gwalior SOCE unit will be entirely operationalized soon. Both the above units are under franchise owned and Shalby Operated (FOSO) model. I am also glad to inform that we have signed a MOU in Aurangabad under SOCE franchise and in the process of taking over all operations in our brand name with whom we have signed MOUs so far. Moreover, our focus remains on capitalizing our expertise and excellence in Orthopedics to have over 50 Shalby franchise hospitals across India within the next 3 years

Our implant business made some satisfactory strides during the third quarter of this financial year with revenues of INR 228 million, wherein USA and India contributed 60% and 40% respectively. Our US customer sales mix from retail and wholesale remained at 60% and 40% respectively in Q3 FY23. With all the efforts to improve implant production, we are now able to produce average ~4,500 components per month from 3,000 components during the first quarter of FY23. We have strengthened our senior leadership team by onboarding two very senior talent in the last quarter at SAT. Further, we are staying focused on adding more talent and building a strong team with the right attitude, shifting our sales to retail customer mix from wholesale, continuously increasing operational capacity and thereby efficiencies, adding new products pipeline supported with extensive research & development activities and substantially bringing down our procurement costs. We continue to receive very positive response from the consumption of our ShalbyConsensus implants in our hospitals. I am very glad to mention that we have now launched our high-quality Knee and Hip Implants for other surgeons and hospital groups in India as per our plan and initial response has been encouraging. We are also to receive the registration and license approval to sell our implants in Indonesia in the next quarter.

With all the key strategies in place, our team is extremely committed on flawless execution of these strategies. Shalby is well poised to deliver double digit growth in the hospital business with sustainable profitability, deepen and increase our footprints by adding Orthopedic units under SOCE and hit the coveted milestone of INR 100 crores and be EBITDA positive in implant business in this fiscal year. All this, in turn, will drive to create sustainable value for all stakeholders at Shalby.

Result PDF

Healthcare facilities company Shalby announced Q2FY23 results:

  • Total Revenues of Rs. 1,830 million, growth of 13.5% YoY (excluding vaccination and covid revenue)
  • EBITDA of Rs. 437 million with EBITDA margins of 24%
  • Profit After Tax was Rs. 218 million, growth of 31% YoY
  • Basic EPS of Rs. 2.03, growth of 32% YoY
  • Bed occupied during the quarter were 600, with occupancy rate of 16%
  • In patients count of 12,606, growth of 19% YoY
  • Total Surgery count of 6.806, growth of 10% YoY

 

Result PDF

Healthcare Facilities firm Shalby Announced Q1FY23 Result :

  • Shalby Hospital Business Registered Quarterly Revenues of Rs. 1,810 million up by 19%, and EBITDA of Rs. 428 million up by 32% with margins of 24%, primarily driven by increase in InPatients count by 15% and Total Surgery count up by 30% quarter on quarter basis.
  • Total Revenues of Rs. 1,810 million, growth of 19% QoQ
  • EBITDA of Rs. 426 million with EBITDA margins of 24%
  • Profit After Tax was Rs. 214 million, growth of 36% QoQ
  • Basic EPS of Rs. 1.99, growth of 37% QoQ
  • Bed occupied during the quarter were 557, with occupancy rate of 45%
  • In patients count of 11,044, growth of 15% QoQ
  • Total Surgery count of 7,211, growth of 30% QoQ

Mr. Shanay Shah, President said: “I am happy to report that Shalby has registered ever highest Revenue in the first quarter of FY23 with high double growth of elective surgeries. During the quarter, a total of 7,211 elective surgeries were performed, grew by 30% QoQ as compared to 5,558 in Q4 FY22. We saw a jump of 15% for In-patients counts in Q1 FY23. Occupied beds increased to 557 up by 12% in Q1 FY23 as compared to 499 in Q4 FY22. ARPOB an ALOS were recorded at Rs.35,304 and 4.08 respectively in Q1 FY23 vis-à-vis Rs 33,707 and 4.12 in the previous quarter. Our core specialty such as Arthroplasty, Oncology, Cardiac Science, Orthopedic, Critical care & General Medicine, and Neurology contributed 84% to the revenues respectively in Q1 FY23.

International revenue recorded at Rs 24 million, grew by in 47% QoQ with majority of the patients are flying from Kenya, Tanzania, Uganda, Sudan, UAE, Nepal and Bangladesh in Q1 FY23. Home care business has shown a good pick up with revenue of Rs. 21.5 million, grew by 13% QoQ with patient served count of 5,868 in Q1 FY23. The Shalby Academy vertical also showed great acceptance with 578 students enrolled for various healthcare programs during Q1 FY23.

Our Realized Return on Capital Employed from hospital business has increased to 17% in Q1 FY23 from 12% in Q4 FY22. We have closed the quarter with a net cash balance of Rs. 439 million at group level and are well positioned to fund our strategic growth plans. Shalby continued to add many milestones backed by clinical excellence and patient satisfaction. We are proud to make a positive difference in people lives.

Result PDF

Healthcare Facilities firm Shalby declares Q4FY22 result:

  • Hospital Performance Highlights: FY2022 vs FY2021
    • Total Revenues of Rs. 6,598 million, growth of 54% YoY
    • Operating EBITDA of Rs. 1,426 million with EBITDA margins of 22%
    • Profit After Tax was Rs. 698 million, growth of 63% YoY
    • Realized Return on Capital Employed improved to 14%, compared to 8% in FY21
    • Bed occupied during the quarter were 563, with occupancy rate of 46%
    • In patients count of 40,603, growth of 41% YoY
    • Total Surgery count of 20,240, growth of 70% YoY
  • Hospital Performance Highlights: Q4 FY2022 vs Q4 FY2021
    • Total Revenues of Rs. 1,523 million, growth of 6% YoY
    • Operating EBITDA of Rs. 323 million with EBITDA margins of 21%
    • Profit After Tax was Rs. 157 million, growth of 42% YoY
    • Bed occupied during the quarter were 499, with occupancy rate of 42%
    • In patients count of 9,629, growth of 11% YoY
    • Total Surgery count of 5,558, growth of 1.6% YoY

Mr. Shanay Shah, President said: “Shalby delivered a strong performance during the year and I am pleased that Shalby as a hospital group was able to support the Covid-19 patients especially during the second wave of Covid-19 which impacted the lives of many. In the second half of the year, we saw a strong recovery of elective surgeries which continues to drive our core specialty revenues.

During the year, a total of 20,240 elective surgeries were performed, an increase of 70% on YoY basis. We saw a strong jump of 41% for in-patient count and travel of international patients has also resumed. Occupied beds increased to 563 up by 31% in FY22 from 428 occupied beds in FY21. ARPOB and ALOS were recorded at Rs. 33,707 and 4.55 days in FY22 vis-a-vis Rs. 27,400 and 5.42 days in FY21. Our core specialty such as Arthroplasty, Critical care & General Medicine, Oncology, Cardiac Science, Orthopaedic, Neurology and Nephrology contributed 29%, 22%, 9%, 8%, 8%, 5% and 3% to the revenues respectively. Continued generation of strong cash flow from hospital operation of Rs. 1,238 million helped to strengthen our balance sheet further. Our Realized Return on Capital Employed has increased from 8% in FY21 to 14% in FY22. We have closed the year with a net cash balance of Rs. 475 million at group level and are well positioned to fund our strategic growth plans.

Shalby has evolved and become a true multi-specialty hospital group which is backed by clinical excellence and patient delight. Shalby Jaipur created history with 200 Joint Replacement surgeries in a month by a single Orthopedic surgeon. We at Shalby units, have successfully completed total 28 Kidney and Liver transplants in FY22. We continue to focus improving internal systems and processes. We have also successfully implemented SAP in February 2022 and this strategic implementation aims to strengthen our financial & operational processes by improvising database management, administration, security, real-time access and advance analytics to support the business decisions.”

Result PDF

Trending News

Larsen & Toubro wins ₹1,000-2,500 cr Mumbai Metro order.

Larsen & Toubro’s Transportation Infrastructure business has won a significant (₹1,000–2,500 crore) order from Mumbai Metropolitan Region Development Authority for Package CA-298 of Mumbai Metro Line-4. 

Published on 26-Dec-2025 09:06

India's utility vehicle exports surpass passenger cars

According to media sources, India’s automobile export profile has hit a milestone, with utility vehicles such as SUVs, MPVs and MUVs overtaking traditional passenger cars in overseas shipments for the first time in November 2025. 

Published on 26-Dec-2025 09:05

KNR Constructions sells road SPVs for ₹1,543 cr

KNR Constructions Limited has signed share purchase agreements with Indus Infra Trust for the sale of its entire 100% stake, including subordinate debt, in four road SPVs—KNR Palani Infra, KNR Ramagiri Infra, KNR Guruvayur Infra and KNR Ramanattukara Infra. 

Published on 26-Dec-2025 09:04

Supreme Industries bags ₹54 cr BPCL order

Supreme Industries has received a Letter of Acceptance from Bharat Petroleum Corporation Limited (BPCL) for a repeat order of 2,00,000 units of 10 Kg composite LPG cylinders. 

Published on 26-Dec-2025 09:03

Credit card spending declines 11.9%.

According to RBI data, total credit card spending declined 11.9% MoM to around ₹1.9 lakh crore in November from ₹2.1 lakh crore in October, reflecting post-festive normalisation, though spends rose nearly 12% YoY from ₹1.71 lakh crore a year ago. 

Published on 26-Dec-2025 09:02

Government bans new mining in Aravalli region

As per media sources, the government has directed state government to impose a complete ban on granting new mining leases across the Aravalli region to preserve the mountain range as a continuous geological ridge and to curb unregulated mining. 

Published on 26-Dec-2025 09:01

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status